Therapix Biosciences announces results in its pre-clinical study of THX-210
Therapix Biosciences announced positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide, or PEA. This study is consistent with Therapix's pipeline to develop cannabinoid based therapies. THX-210 is intended for the treatment of epilepsy, as well as inflammatory conditions. The study consisted of in vitro tests which examined potential synergy between CBD and PEA. The study was performed in hepatocytes model of fat accumulation, where each compound was tested in a range of concentrations. In these tests, PEA had shown no effect of its own, while the effect of CBD was enhanced by the addition of PEA, lowering the required effective concentration of CBD. Thus, THX-210 has demonstrated superior efficacy as compared to the effect of CBD alone.